KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13. November 2023 08:00 ET
|
KALA BIO, Inc.
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ---- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with...
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20. September 2023 16:01 ET
|
KALA BIO, Inc.
ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award...
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
05. September 2023 08:00 ET
|
KALA BIO, Inc.
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
04. August 2023 08:00 ET
|
KALA BIO, Inc.
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA,...
KALA BIO to Participate in Upcoming Investor Conferences in August
02. August 2023 16:01 ET
|
KALA BIO, Inc.
ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
Kala Pharmaceuticals Announces Name Change to KALA BIO
02. August 2023 08:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19. Juli 2023 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement...
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23. Juni 2023 16:01 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options and restricted stock units (RSUs)...
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
02. Juni 2023 08:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
09. Mai 2023 08:00 ET
|
Kala Pharmaceuticals, Inc.
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024...